iX Biopharma Advances Global Licensing of Wafermine

iX Biopharma Ltd. (SG:42C) has released an update.

iX Biopharma is escalating its efforts to out-license Wafermine, its non-opioid pain treatment with potential applications in Complex Regional Pain Syndrome and depressive disorders, by partnering with the global life sciences advisory firm Kybora. The company is setting its sights on global markets, banking on Wafermine’s US FDA Orphan Drug Designation, which promises 7 years of market exclusivity and development incentives. With a focus on safety and effectiveness, Wafermine represents a promising alternative to opioid painkillers and a potential breakthrough for treatment-resistant depression.

For further insights into SG:42C stock, check out TipRanks’ Stock Analysis page.